The QualityStocks Daily Friday, July 21st, 2023

Today's Top 3 Investment Newsletters

QualityStocks(GFAI) $6.4400 +57.46%

INO Market Report(SIRI) $7.8100 +42.26%

MarketBeat(NOTV) $6.8200 +34.52%

The QualityStocks Daily Stock List

Camber Energy (CEI)

StockMarketWatch, StockEarnings, Schaeffer's, StocksEarning, MarketClub Analysis, OTCtipReporter, PennyStockScholar, Profitable Trader Authority, InvestorPlace, BUYINS.NET, QualityStocks, StockOnion, Penny Pick Finders, PennyStockProphet, Planet Penny Stocks, Penny Stock General, Shiznit Stocks, Stock Commander, Buzz Stocks, TradersPro, OTCBB Journal, The Online Investor, Broad Street, MicroCapDaily, TopPennyStockMovers, Penny Stock Prodigy, OnPointStockAlert, AwesomeStocks, Fast Money Alerts, InvestorSoup,, FreeRealTime, Equity Observer, Beacon Equity Research, Damn Good Penny Picks, INO Market Report, MegaPennyStocks, Monster Alerts, Penny Picks, AllPennyStocks, Penny Stock Finder, Penny Stock Titans, PoliticsAndMyPortfolio, Stock Beast, Stock Market Watch, Stock Preacher, StreetInsider, SuperStockTips, The Street and Penny Stock Craze reported earlier on Camber Energy (CEI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Camber Energy Inc. (NYSE American: CEI) (FRA: 58L5) is an independent oil and natural gas firm that is focused on acquiring, developing and selling natural gas, crude oil and natural gas liquids from productive geological formations which include the Eagle Ford and Austin Chalk formations that are found in the Karnes, Wilson and Gonzales counties in Texas’ city of San Antonio.

The firm has its headquarters in Houston, Texas and was incorporated in 2003, December 16th by James J. Cerna and William A. Sawyer. Prior to its name change in January 2017, the firm was known as Lucas Energy Inc. Its operations mainly focus on South and West Texas and Central Oklahoma. The firm’s sales are made on a month-to-month basis and it mainly serves consumers in the U.S.

The enterprise holds interests in about 3600 acres in producing fields in the Permian Basin’s Central Basin platform in West Texas, under a joint agreement. It also holds interests in roughly 13000 acres in producing fields found mainly in the Hunton formation in the Payne, Logan and Lincoln counties in Central Oklahoma, as well as in the upper Wolfberry shale and the Cline shale, in the state of Texas.

The company recently acquired majority stake in Simson-Maxwell Ltd, which manufactures and supplies power generation products and industrial engines, among other solutions. This move will help to position the company for additional expansion throughout North America while strengthening the already-established platform, which will not only bring in additional revenues but also investments into the company.

Camber Energy (CEI), closed Friday's trading session at $1.22, up 53.3241%, on 72,763,881 volume. The average volume for the last 3 months is 32.528M and the stock's 52-week low/high is $0.6045/$21.435.

Fresh Tracks Therapeutics (FRTX)

QualityStocks, MarketClub Analysis, 360wallstreet and 247 Market News reported earlier on Fresh Tracks Therapeutics (FRTX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Fresh Tracks Therapeutics Inc. (NASDAQ: FRTX) (FRA: VCC) is a clinical-stage pharmaceutical firm that is focused on developing a range of prescription therapeutics for the treatment of inflammatory, autoimmune and other debilitating illnesses.

The firm has its headquarters in Boulder, Colorado and was incorporated in 2009 by Andrew D. Sklawer and Reginald L. Hardy. Prior to its name change in September 2022, the firm was known as Brickell Biotech Inc. It operates as part of the biotechnology industry, under the healthcare sector. The firm serves consumers around the world, with a focus on those in the United States.

The company’s primary focus is to transform the lives of patients by developing ground-breaking and innovative prescription therapeutics. It is party to license and collaboration agreements with AnGes Inc., Dr. Nicholas S. Bodor, Bodor Laboratories Inc., Voronoi Inc. and Carna Biosciences Inc.

The enterprise’s product pipeline is comprised of a covalent stimulator of interferon genes inhibitor known as BBI-10, for the potential treatment of rare genetic and auto-inflammatory illnesses; an oral DYRK1A inhibitor dubbed BBI-02for the treatment of inflammatory and autoimmune illnesses; and sofpironium bromide, which has completed Phase 3 trials evaluating its effectiveness in treating primary auxiliary hyperhidrosis.

The firm, which recently rebranded and established a scientific advisory board, remains focused on its mission to develop new therapies that restore immune balance. The success and approval of its therapies will not only benefit patients with a range of indications but also significantly bolster its overall growth.

Fresh Tracks Therapeutics (FRTX), closed Friday's trading session at $0.95, up 39.5827%, on 32,527,752 volume. The average volume for the last 3 months is 29.097M and the stock's 52-week low/high is $0.4495/$4.64.

22nd Century Group (XXII)

Schaeffer's, TraderPower, Broad Street, TradersPro, PennyStocks24, QualityStocks, BUYINS.NET, Fierce Analyst, StockMarketWatch, AwesomeStocks, InvestorPlace, Small Cap Firm, StockWireNews, Pennybuster, MarketBeat, OTCBB Journal, StocksImpossible, Ceocast News, StockStreetWire,, The Street, First Penny Picks, StreetInsider, Money Morning, Promotion Stock Secrets, InvestmentHouse, Wealth Insider Alert, Daily Trade Alert, Investing Futures, Jet-Life Penny Stocks, Nathan Gold, MarketClub Analysis, Investing Daily, StrategicTechInvestor, Top Pros' Top Picks, Shah's Insights & Indictments, CFN Media Group, Street Insider, DreamTeamNetwork, Stockgoodies, The Online Investor, Insider Financial, Leading Penny Stocks, Wise Alerts, Proactivecrg, Penny Stock, Mega Stock Alerts, SmallCapNetwork and ProTrader reported earlier on 22nd Century Group (XXII), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

22nd Century Group Inc. (NASDAQ: XXII) is a biotechnology firm that is focused on the development of disruptive plant-based solutions for the pharmaceutical, consumer product and life science markets.

The firm has its headquarters in Buffalo, New York and was incorporated in 2005, on September 12th. It operates as part of the scientific research and development services industry. The firm serves consumers around the globe and has four companies in its corporate family.

The company focuses on technologies which alter the level of cannabinoids in cannabis or hemp plants and the level of nicotine in tobacco plants, through modern plant breeding techniques, as well as through gene-editing and genetic engineering. It is party to a collaboration with Keygene N.V. which entails the development of cannabis/hemp plants for extraordinary cannabinoid profiles and other superior traits for agricultural, therapeutic and medical uses.

The enterprise is involved in the development of less harmful or modified risk tobacco products with low nicotine content, under the Moonlight Menthol and Moonlight names. These include a variable nicotine research cigarette dubbed Spectrum, which has been developed for use in independent clinical studies. It also develops a VLN 2.0 (very low nicotine) prototype cigarette through the use of its non-genetically modified technology.

The FDA recently authorized the marketing of the firm’s VNL Menthol King and VLN King reduced nicotine cigarettes, making it the first product to receive modified risk tobacco product designation. This move will not only transform the tobacco industry but also have a positive effect on the firm’s investments and growth.

22nd Century Group (XXII), closed Friday's trading session at $4.85, up 31.0811%, on 29,096,542 volume. The average volume for the last 3 months is 6.24M and the stock's 52-week low/high is $2.19/$31.575.

Quoin Pharmaceuticals (QNRX)

StocksEarning, QualityStocks, PCG Advisory, MarketBeat, FreeRealTime, Schaeffer's and Money Wealth Matters reported earlier on Quoin Pharmaceuticals (QNRX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Quoin Pharmaceuticals Ltd (NASDAQ: QNRX) (FRA: 2EB) is a specialty pharmaceutical firm that is engaged in the development and commercialization of therapeutic products for orphan and rare indications.

The firm has its headquarters in Ashburn, Virginia and was incorporated in 2018, on March 5th. Prior to its name change, the firm was known as Cellect Biotechnology Ltd. It operates as part of the pharmaceutical and medicine manufacturing industry, under the healthcare sector. The firm serves consumers around the globe.

The company’s technology platform, dubbed ApoGraft, uses functional selection to pick stem cells that can enhance the effectiveness and safety of regenerative medicine and cell therapies.These stem cells flourish in an environment where other cells would’ve been eliminated, as their primary role is damaged tissue reconstitution. The platform exploits a stem cell characteristic associated with apoptosis, which is the process of programmed cell death. Efficient selection allows for retention of majority of stem cells while neutralizing harm.

The enterprise’s product pipeline comprises of a topical lotion dubbed QRX006, which is indicated for the treatment of rare skin diseases; a topical lotion known as QRX004, developed to treat recessive dystrophic epidermolysis bullosa; and a potential therapy dubbed QRX003, which is indicated for the treatment of Netherton Syndrome.

The company recently entered into an exclusive agreement with Orpharm LLC, for its QRX003 therapy. This distribution agreement will enable the therapy to be commercialized in Russia, which will not only bring in significant revenue but also extend their consumer reach, which may encourage more investments into the company.

Quoin Pharmaceuticals (QNRX), closed Friday's trading session at $9.09, up 39.6313%, on 6,239,786 volume. The average volume for the last 3 months is 6,000 and the stock's 52-week low/high is $5.04/$337.32.

Rafarma Pharmaceuticals (RAFA)

QualityStocks, PennyStocks24, TradersPro, Stocks That Move, Real Pennies, FeedBlitz, WallstreetSurfers, SeriousTraders, PennyStocksSMS, Penny Stock SMS Publisher, Penny Stock Rumble and Greenbackers reported earlier on Rafarma Pharmaceuticals (RAFA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Rafarma Pharmaceuticals Inc. (OTC: RAFA) is a diversified multi-product pharmaceutical firm involved in the production and sale of drugs, specialty pharmaceuticals and generic antibiotics.

The firm has its headquarters in Sandy, Utah and was incorporated in 2004, on May 26th. Prior to its name change in October 2012, the firm was known as Johnston Acquisition Corporation. It operates as part of the drug manufacturers-specialty and generic industry, under the healthcare sector. The firm serves consumers around the globe.

The company, which has a manufacturing and distribution facility in Russia, has operated as a subsidiary of R&D Biocogency Laboratories Inc. Limited from October 19th 2020. It is party to a collaboration agreement with PlantEXT Limited, which entails the research and manufacture of the first medical cannabis suppositories for patients suffering from inflammatory bowel disease.

The enterprise produces a range of generic and alternative basic pharmaceutical products available for sale at 'mass market' prices. It provides antibiotics of non-ß structure, cephalosporin-based products and anti-cancer drugs in the form of injections, ampulla packaged products, child suspensions, tablets, and capsules. It also offers drugs for accidental wounds, inflammatory eye diseases, and immunological disorders.

The firm recently announced its plans to open an enterprise in Hong Kong in collaboration with its partner, Long Sheng Pharma Limited, which manufactures pharmaceutical equipments. This move may help extend its consumer reach while also generating value for its shareholders.

Rafarma Pharmaceuticals (RAFA), closed Friday's trading session at $0.29, even for the day. The average volume for the last 3 months is 1,200 and the stock's 52-week low/high is $0.22/$0.738125.

Tenaz Energy (ATUUF)

MarketBeat reported earlier on Tenaz Energy (ATUUF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tenaz Energy Corp (OTC: ATUUF) (TSE: TNZ) (FRA: 7F4) is an energy firm that is focused on acquiring and developing oil and gas assets.

The firm has its headquarters in Calgary, Canada and was incorporated in 2007, on June 8th. Prior to its name change in October 2021, the firm was known as Altura Energy Inc. It operates as part of the oil and gas E&P industry, under the energy sector. The firm serves consumers around the globe.

The company has two operating segments; the Canadian business unit and the Netherlands business unit. It generates revenue from the sale of petroleum and natural gas products such as heavy crude oil, light crude and medium crude oil, natural gas, and natural gas liquids. The majority of its revenue is derived from the sale of heavy crude oil.

The enterprise’s domestic operations in Canada comprise of a semi-conventional oil project in the Rex member of the Upper Mannville group at Leduc-Woodbend in central Alberta. Its semi-conventional development project is located in the Leduc-Woodbend area of Alberta, Canada. This project targets the Rex zone within the Manville formation and has production of approximately 2,337 barrels of oil equivalent (boe) per day. On the other hand, its Netherlands gas assets are located in the Dutch sector of the North Sea. The enterprise also has an ownership interest in Noordgastransport B.V. (NGT), which holds gas gathering and processing networks in the Dutch North Sea.

The firm recently closed the previously announced acquisition of 100% of the shares of XTO Netherlands Ltd. from XH LLC, a wholly owned subsidiary of ExxonMobil Corporation. This move may open the firm up to new growth and investment opportunities and in turn, help create shareholder value.

Tenaz Energy (ATUUF), closed Friday's trading session at $2.63, off by 2.2305%, on 1,200 volume. The average volume for the last 3 months is 29,780 and the stock's 52-week low/high is $1.0329/$2.8585.

Bayhorse Silver (BHSIF)

We reported earlier on Bayhorse Silver (BHSIF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bayhorse Silver Inc. (OTCQB: BHSIF) (CVE: BHS) (FRA: 7KXN) is a junior natural resource firm that is focused on acquiring, exploring for and developing natural resource properties.

The firm has its headquarters in Burnaby, Canada and was incorporated in 2004, on April 6th. Prior to its name change in December 2013, the firm was known as Kent Exploration Inc. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm serves consumers around the globe.

The company operates through the Canada and USA geographical segments. It is party to an Offtake Agreement for the sale of its eventual silver/copper concentrate produced from the Bayhorse Silver Mine with Ocean Partners UK Limited.

The enterprise primarily explores for silver, gold, zinc, copper, antimony, lead, and other metals. It holds a 100% interest in the Bayhorse Silver Mine Property located in Baker County, Oregon. The Bayhorse mineralization comprises mainly of acanthite, tehrahedrite/tennantite, and occurs in an 80 feet wide and 22 feet thick zone extending for a known 840 feet along an andesite and rhyolite contact. The enterprise has also entered into an option agreement to acquire an 80% interest in the BrandywineAu/Ag project, which is located in British Colombia. The brownfield Brandywine deposit has undergone several exploration phases including bulk tonnage shipments to smelters, extensive drilling, and extensive geochemical and geophysical studies.

The company, which recently gave a corporate update on its operations, is focusing its main efforts on the Bayhorse Silver Mine.

Bayhorse Silver (BHSIF), closed Friday's trading session at $0.01692, even for the day. The average volume for the last 3 months is 142,451 and the stock's 52-week low/high is $0.006/$0.0425.

Multi Ways (MWG)

We reported earlier on Multi Ways (MWG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Multi Ways Holdings Limited (NYSE American: MWG) is a holding firm engaged in the supply of a range of heavy construction equipment for sale and rental globally.

The firm has its headquarters in Singapore and was incorporated in 1988. It operates as part of the rental and leasing services industry, under the industrials sector. The firm serves consumers around the globe, with a focus on those in Australia, Indonesia, Singapore, the Philippines, the UAE and Maldives.

The enterprise, which is a subsidiary of MWE Investments Limited, is a widely established firm as a reliable supplier of new and used heavy construction equipment with over two decades of experience in the business. It operates through its subsidiaries, which include MWE Holdings Limited (MWE Holdings) and Multi Ways Equipment Pte Ltd (Multi Ways SG).

The enterprise supplies and rents used and new heavy construction equipment in the infrastructure, offshore and marine, building construction, mining and oil and gas industries. It provides material-handling equipment such as crawler cranes, rough terrain cranes, scissor lifts, forklifts, boom-lifts, and telescopic handlers; earth-moving equipment, such as bulldozers, off-terrain dump trucks, excavators, and wheel loaders; air compressors, generators, lighting towers, and welding machines; and road-building equipment comprising motor graders, vibrating compactors, asphalt finishers, skid loaders, backhoe loaders, hand rollers, and mini excavators.

The company, whose latest financial results show increases in its revenues, remains focused on investing in the expansion and renewal of its fleet of heavy construction equipment in an effort to meet growing demand. This may, in turn, bolster the company’s overall growth.

Multi Ways (MWG), closed Friday's trading session at $0.5998, up 0.341442%, on 142,451 volume. The average volume for the last 3 months is 15,000 and the stock's 52-week low/high is $0.5027/$16.33.

Pampa Metals (PMMCF)

We reported earlier on Pampa Metals (PMMCF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Pampa Metals Corporation (OTCQB: PMMCF) (CNSX: PM) (FRA: FIRA) is a mineral exploration firm that is focused on acquiring and exploring for base and precious metals in projects in Chile.

The firm has its headquarters in Vancouver, Canada and was incorporated in 1999. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm serves consumers around the globe.

The company owns an approximately 60,000-hectare portfolio of 8 projects for copper and gold located along mineral belts in Chile. Its projects include the Arrieros project, Block 2, Block 3, Block 4, the Redondo-Veronica project, the Cerro Blanco project, the Cerro Buenos Aires project and the Morros Blancos project. The Arrieros project is located in northern Chile, roughly 25 km south of the mining town of Calama. The Block 2 project is located in northern Chile and is centered approximately 120 km east of the coastal port city of Antofagasta. The Block 3 project is located in northern Chile and is centered approximately 170 km southeast of the coastal port city of Antofagasta. The Redondo-Veronica is located in northern Chile and is centered approximately 150 km east of the coastal port city of Antofagasta.

The enterprise, which recently reported assay results from a three-hole diamond drilling program recently completed on its 100% owned Buenavista target located in northern Chile, remains committed to assessing other high potential opportunities for the discovery of large-scale copper deposits in the Americas.

Pampa Metals (PMMCF), closed Friday's trading session at $0.034, even for the day. The average volume for the last 3 months is 1.578M and the stock's 52-week low/high is $0.0081/$0.2408.

HIVE Blockchain Technologies Ltd. (HIVE)

QualityStocks, InvestorPlace, MarketClub Analysis, MarketBeat, StreetInsider, Early Bird,, StockMarketWatch, Zacks, CryptoCurrencyWire, Greenbackers, Hit and Run Candle Sticks, Barchart, Stock Market Watch, StockOodles, StreetAuthority Daily, The Night Owl, The Online Investor, TopStockAnalysts, Wall Street Resources, WealthMakers and smartOTC reported earlier on HIVE Blockchain Technologies Ltd. (HIVE), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A recent court ruling on the SEC/Ripple case brought a wave of celebration within the crypto industry. Judge Analisa Torres delivered a significant verdict by declaring that XRP should not be categorized as a security. Many crypto enthusiasts perceive this ruling as an encouraging sign that similar assets will thrive in the United States. However, legal experts caution that further regulatory clarity is still necessary.

Bitcoin, as a commodity, benefits from a clearer regulatory framework and oversight from specific agencies. Unfortunately, this is not the case for the majority of cryptocurrencies.

The U.S. Securities and Exchange Commission (SEC) argues that most cryptocurrency assets qualify as securities and thus fall under the jurisdiction of securities laws. Consequently, the SEC has initiated enforcement actions against token issuers and crypto exchanges such as Coinbase and Binance, which facilitate the trading of these tokens.

The recent court ruling, which determined that XRP itself is not an investment contract, has inspired hope among some members of the crypto industry. They anticipate that the SEC will adopt a more hands-off approach in the future. As a result of this ruling, other crypto assets previously considered securities, such as Polygon and Solana, experienced a rally in response to the news.

According to Jason Gottlieb, a partner at Morrison Cohen, the ruling marks a departure from the SEC’s previous cases involving Kik and Telegram. In those cases, all initial coin offerings were viewed as part of a single investment scheme. Now, it may be possible to trade crypto assets as unrestricted securities, provided they demonstrate sufficient decentralization or are not directly sold to retail investors. Gottlieb also believes that the Ripple ruling makes it challenging to argue that staking rewards should be classified as securities.

In addition to offering more clarity for token issuers, the Ripple court decision also grants exchanges greater flexibility regarding the assets they can list. The order further highlighted that while XRP sales to institutional investors violated securities laws, trading XRP on exchanges by retail investors did not.

This ruling could potentially impact the lawsuits filed by the SEC against Coinbase and Binance, both accused of operating unlicensed securities exchanges. Paul Grewal, Coinbase’s head legal officer, stated that the court order in the Ripple case strengthens the exchange’s legal standing. Grewal expressed confidence in the case even before the decision and believes that this ruling further solidifies their position.

While the crypto industry views the Ripple court finding as a temporary victory, it is essential to acknowledge that this ruling may not serve as the final verdict for two crucial reasons. Firstly, the SEC retains the option to appeal the judge’s decision in the Ripple case. Secondly, the ultimate determination regarding the regulatory classification of crypto assets may arise from new legislation passed by Congress, an idea supported by SEC Commissioner Hester Peirce.

Industry players such as HIVE Blockchain Technologies Ltd. (NASDAQ: HIVE) (TSX.V: HIVE) are likely following the current litigation against Coinbase and Binance to see how this recent ruling affects the outcomes of those ongoing cases.

HIVE Blockchain Technologies Ltd. (HIVE), closed Friday's trading session at $5.33, off by 2.2018%, on 1,577,644 volume. The average volume for the last 3 months is 1.022M and the stock's 52-week low/high is $1.36/$7.525.

atai Life Sciences N.V. (ATAI)

QualityStocks, MarketBeat, The Online Investor, StockMarketWatch, StreetInsider, Dynamic Wealth Report, Uncommon Wisdom,, MarketClub Analysis, BestOtc, CRWEFinance, CRWEPicks, CRWEWallStreet, DrStockPick, InsiderTrades, PennyOmega, PennyToBuck, Schaeffer's, Small Caps, StockHotTips, TraderPower, Awareness Stocks, StockOodles, Street Insider, The Street, TopPennyStockMovers and ProTrader reported earlier on atai Life Sciences N.V. (ATAI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Research into psychedelics is increasingly revealing that these purportedly dangerous drugs may have potent mental health benefits. While modern antidepressants work by influencing the levels of hormones such as serotonin in the brain, psychedelics seem to deliver their benefits by influencing the mind and perception.

Their unique effects allow psychedelics to deliver long-term benefits against a myriad of mental disorders, with minimal side effects.

Clinical studies have found that psychedelics, including psilocybin, can treat conditions such as major depressive disorder when conventional treatments have failed. A recent study looking at the potential benefits and risks of microdosing psychedelics has found that there may be an association between microdosing and increased authenticity.

Microdosing refers to the practice of taking tiny doses of psychedelics while remaining within the therapeutic dose to avoid experiencing any mind-bending effects. It has gained popularity in recent years as more people turn away from conventional treatments in favor of psychedelics to treat conditions like anxiety and depression.

According to the recent study, microdosing psychedelics may result in a heightened feeling of authenticity in users. Researchers recruited 18 participants and collected data over the course of a month during 192 observation sessions. The individuals were asked to provide assessments of their state of authenticity on nonmicrodosing and microdosing days.

The research team also recorded the activities the participants engaged in over the study period and the level of satisfaction they drew from these activities.

Mixed-effects models were used to analyze the data after emotional states, trait authenticity and demographic information were used as control variables. The researchers measured state authenticity using the Real-Self Overlap Scale while an indicator variable was used to assess the microdosing. A mixed-effects model was then used to test the hypotheses that microdosing psychedelics was somehow associated with increased authenticity.

The researchers found that microdosing resulted in elevated levels of the of state authenticity on the day of dosing and the day after. They also discovered that the 18 study participants found more satisfaction in daily activities after microdosing psychedelics and were more likely to cook, read write and engage in chores.

The findings suggest that microdosing psychedelics may make users feel more authentic and increase the satisfaction they derive from daily activities. The researchers behind the study indicate that microdosing may help individuals feel more connected to their emotions and thoughts and make it easier for them to act in ways that genuinely mirror their internal desires and values.

While these studies point to the potential benefits of microdosing, it is important to keep in mind that these psychedelics could pose some risks to users, which is why a lot of companies such as atai Life Sciences N.V. (NASDAQ: ATAI) are focusing their drug-development efforts on formulations that require to be used in a clinical setting.

atai Life Sciences N.V. (ATAI), closed Friday's trading session at $2.09, up 0.966184%, on 1,022,019 volume. The average volume for the last 3 months is 240,771 and the stock's 52-week low/high is $1.14/$4.96.

ElectraMeccanica Vehicles Corp. Ltd. (SOLO)

Green Car Stocks, InvestorPlace, QualityStocks, StocksEarning, Kiplinger Today, Schaeffer's, MarketClub Analysis, StockMarketWatch, TradersPro, StockEarnings, BUYINS.NET, Trades Of The Day, MarketBeat, The Street, Daily Trade Alert, TopPennyStockMovers, The Online Investor, VectorVest, PoliticsAndMyPortfolio, Small Cap Firm, GreenCarStocks, SmallCapVoice, Eagle Financial Publications and Cabot Wealth reported earlier on ElectraMeccanica Vehicles Corp. Ltd. (SOLO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

As the United States, the United Kingdom and other large economies pledged to transition from dirty fuels to clean energy and electrify their lineups, major companies such as Amazon are following suit. The e-commerce giant plans on electrifying its entire fleet of delivery vans over the decade to cut emissions from transportation.

At the time of writing, Amazon had integrated more than 5,000 electric cars into its fleet with EV company Rivian acting as the primary supplier. Crossing the 5,000 mark represents a significant milestone for the two companies and indicates that the electrification of Amazon’s fleet is well on its way.

Amazon partnered with electric van manufacturer Rivian in 2021, kicking off the start of electric van deliveries to the world’s largest e-commerce company in the U.S. The partnership started with a trial period where Amazon tested the capabilities of Rivian Electric Delivery Van (EDV) prototypes before placing an order of 100,000 electric vans from Rivian. Amazon hopes to have all 100,000 electric vans on the road by 2030 as part of its pledge to achieve net-zero emissions by 2040.

The online retailer is one of the largest emitters of carbon in the country, releasing around 71.54 million tons of carbon dioxide in 2021 amid rapid expansion due to the pandemic. According to Amazon, more than 5,000 EDVs from Rivian are currently in operation in 800 locations across the continental U.S.

This announcement coupled with Rivian exceeding its quarterly electric vehicle delivery quotas over the last quarter led to an increase in the EV maker’s share prices.

However, despite exceeding EV delivery quotas, Rivian has been plagued with issues such as production delays, supply chain constraints and sustained losses. As with most automakers, Rivian also had to contend with the global semiconductor shortage that crippled the auto supply chain and forced several automakers to halt production until they could find alternative semiconductor sources.

Rivian was unable to meet its 2022 production estimates but weathered supply chain shortages and even factory fires to reduce production and wait times. Reducing its delivery wait times has allowed Rivian to begin catching up to its previously missed annual delivery goals. With the entirety of Amazon’s electric fleet coming from Rivian, it is clear that the EV maker has been integral to the online retailer’s electrification efforts.

Amazon’s delivery fleet of more than 40,000 vehicles is mainly comprised of gas-powered internal combustion engine cars. Electrifying its entire fleet will allow the online retail giant to significantly reduce its carbon emissions and take it a step closer to achieving its net-zero carbon goals.

If other EV manufacturers such as ElectraMeccanica Vehicles Corp. Ltd. (NASDAQ: SOLO) could get large orders similar to what Rivian secured from Amazon, the push for electrification may progress at a faster rate and put the brakes on climate change sooner.

ElectraMeccanica Vehicles Corp. Ltd. (SOLO), closed Friday's trading session at $0.7425, off by 0.067295%, on 240,771 volume. The average volume for the last 3 months is 17,884 and the stock's 52-week low/high is $0.44/$1.87.

The QualityStocks Company Corner

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF)

The QualityStocks Daily Newsletter would like to spotlight Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF).

Eloro Resources (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec, has looked to explore the potential of its flagship Iska Iska tin project in Bolivia. "Having begun drilling work in September 2020, it was not long until the drill team hit a breccia pipe – a geologically significant formation of ore, cemented together by silica. Shortly thereafter, the team would uncover a further 180m of mineralized breccia, cementing the geological potential of the site. Just over two years later, Eloro Resources has now carried out over 85,000m and 122 holes of exploratory drilling within the Iska Iska deposit, with initial results revealing ‘magnificent core, which is remarkably consistent, continuous, and high grade at 90g/t silver equivalent and greater,'" a recent article reads. "Eloro Resources is now targeting the publication of its mineral resource estimate, slated for release in the near future. The company is also simultaneously carrying out exploratory work at Mina Casiterita, an adjoining site that Eloro Resources recently acquired, with the hope of defining the tin porphyry potential of the area. In Executive Vice President of Exploration Bill Pearson's words, the company now faces a ‘remarkable opportunity at Iska Iska to outline two world-class deposits.'"

To view the full article, visit

Eloro Resources Ltd. (TSX.V: ELO) (OTCQX: ELRRF) is a publicly traded exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec.

The company has an option to acquire a 99% interest in the highly prospective Iska Iska Property, classified as a silver-tin polymetallic epithermal-porphyry complex, a significant mineral deposit type in the Potosi Department of southern Bolivia. Iska Iska is a road-accessible, royalty-free property.

Eloro also owns an 82% interest in the La Victoria Gold/Silver Project, located in the North-Central Mineral Belt of Peru, some 50 kilometers south of Barrick’s Lagunas Norte Gold Mine and Pan American Silver’s La Arena Gold Mine. La Victoria consists of eight mining concessions and eight mining claims encompassing approximately 89 square kilometers. La Victoria has good infrastructure, with access to road, water and electricity, and is located at an altitude that ranges from 3,150 meters to 4,400 meters above sea level.

The company has a strong management and technical team working diligently to uncover the value of both Iska Iska and La Victoria. Eloro is based in Toronto, Canada.


Iska Iska – Potosi, Bolivia

Iska Iska is associated with a Miocene possibly collapsed/resurgent caldera, emplaced on Ordovician age rocks with major breccia pipes, dacitic domes and hydrothermal breccias. The property is wholly controlled by the title holder, Empresa Minera Villegas S.R.L. It is located 48 kilometers north of Tupiza city, in the Sud Chichas Province of the Department of Potosi. This is an important mineral deposit type in the prolific South Mineral Belt of Bolivia. Eloro commissioned a NI 43-101 Technical Report on Iska Iska, which was completed by Micon International Limited and is available on Eloro’s website and under its filings on SEDAR.

A fully financed drill program is currently underway on the property, situated near world-class deposits including Silver Sand, San Bartolomé, Pulacayo, San Cristobal, San Vicente, Chorolque, Tasna, Choroma and Siete Suyos. Iska Iska is in the southwest part of the Eastern Cordillera, which hosts a number of major polymetallic mines and mineral deposits. Drilling and continuous channel sampling results have demonstrated some very high metal values, especially silver and tin, within an immense system, where mineralization has been encountered in every drill hole to date. The company believes there is excellent potential for world-class bulk mineable deposits.

La Victoria – Ancash, Peru

The La Victoria project, targeting gold and silver production, is situated near world-class, low-cost gold producers Pan American Silver and Barrick Gold Corporation. Located in Ancash Department, La Victoria sits on the western slopes of the Peruvian Andes. The property is located 12 hours from Lima, with a travel distance of 600 kilometers. The nearest road accessible population centers from La Victoria are Huandoval, Pallasca and Cabana. The project includes four principal mineralized zones in Peru’s prolific North-Central Mineral Belt – San Markito, Victoria, Victoria South and Ccori Orcco – with excellent potential for gold discovery. Operations at La Victoria are planned to proceed with a 2,000-meter diamond drilling program to test targets to outline potential resources at San Markito. Trenching and sampling confirmed high silver values and veins at San Markito in 2020.

Market Outlook

According to industry association The Silver Institute, the outlook for silver demand is exceptionally promising, with global demand forecast to rise to a record high of 1.112 billion ounces in 2022. The increase will be driven by record silver industrial fabrication, which is forecast to improve by 5%, as silver’s use expands primarily in solar energy and electric vehicle (EV) manufacturing. The institute states that government commitments to carbon neutrality have resulted in a rapid expansion of green energy projects, driving record photovoltaic panel installations which are expected to lift silver demand in this segment to an all-time high in 2022.

Rising demand in the electronics industry is also boosting the demand for tin, which is primarily used in solder. The electronics and electrical industries use solders containing 40-70% tin, which provide strong and reliable joints under a variety of environmental conditions. At present, the majority of the assemblers are using patented tin-and-copper-based solders. Mordor Intelligence estimated tin demand at 387 kilotons in 2021 and forecasts demand growth of 2.5% annually through 2027. Over the medium term, surging demand from the EV market and increasing applications in the electrical and electronics industry is expected to drive the market.

Management Team

Thomas G. Larsen is CEO of Eloro. He has more than 40 years of experience in the investment industry, specializing in corporate finance and management of junior resource companies, raising in excess of C$200 million. He previously held the position of President and Chief Executive Officer of Champion Iron Limited. Prior to that, he was President and Chief Executive Officer of Champion Iron Mines Limited.

Dr. Bill Pearson is Executive VP of Exploration for Eloro. He has more than 40 years of direct experience in the exploration and production of minerals worldwide. He played an integral role in the acquisitions of Desert Sun Mining Corp. by Yamana Gold in 2006 and Central Sun Mining by B2 Gold in 2009. He was formerly VP Exploration at Desert Sun Mining and Senior VP at Central Sun Mining.

Miles Nagamatsu, CPA, is CFO at Eloro. He has over 30 years of experience in accounting, management, lending, restructurings and turnarounds. Since 1993, he has acted as a CFO of public and private companies primarily in the mineral exploration and investment management sectors. He holds a Bachelor of Commerce degree from McMaster University.

Osvaldo Arce Burgoa is General Manager at Eloro. He is a geological and mineral processing engineer with 26 years of experience in Bolivia. He is a former President of the Bolivian Geological Society, Main Technical Advisor of the National Mining Corporation (COMIBOL) and has served as exploration manager and chief geologist at various mining and exploration companies. He has authored two books on Bolivian geology and holds a doctorate in mining engineering from Tohoku University in Sendai, Japan.

Eloro Resources Ltd. (OTCQX: ELRRF), closed Friday's trading session at $2.67, up 1.5209%, on 17,884 volume. The average volume for the last 3 months is 63,107 and the stock's 52-week low/high is $2.0179/$3.40.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

National awareness of glioblastoma tumors ("GBM") sustained by Congressional leaders aim to improve efforts to treat brain cancers and ultimately improve patient survival

GBM is a widely occurring, aggressive and effectively incurable brain cancer that few patients survive beyond three years

U.S.-based drug developer CNS Pharmaceuticals is in the midst of a global potentially pivotal clinical trial for its lead pharmaceutical candidate, Berubicin, which it aims to show improves on standard of care chemotherapy agent Lomustine's approach to treating GBM

Berubicin is a novel anthracycline that is practically unique in its ability to cross the blood-brain barrier to directly target tumors, and a Phase I trial of the drug in 2006 produced a surviving patient with over 15 years cancer-free

An interim futility analysis of the current trial is anticipated later this year

A simple search of the Internet shows a number of clinical trials attempting to improve treatment options for glioblastoma ("GBM") brain cancers, and Congress will recognize a National Glioblastoma Awareness Day next month to further support development of effective brain cancer responses. That's because, as the U.S. Social Security Administration acknowledges in its protocols for speeding disability applications through "compassionate allowances," GBM tumors are "the most malignant of the primary brain cancers" and they respond "poorly to all currently available treatments." The protocols for compassionate allowance in GBM cases further note that "prognosis is grim, as most patients die within 2 years and few survive longer than three years" ( Texas-based cancer drug innovator CNS Pharmaceuticals (NASDAQ: CNSP) is nearing the release of its interim analysis for its potentially pivotal clinical trial tracking the effectiveness of drug candidate Berubicin, which has already produced one patient with over 15 years of GBM survival.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Friday's trading session at $2.16, up 0.934579%, on 63,107 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $3.40/$.

Recent News

InMed Pharmaceuticals Inc. (NASDAQ: INM)

The QualityStocks Daily Newsletter would like to spotlight InMed Pharmaceuticals Inc. (NASDAQ: INM).

InMed Pharmaceuticals (NASDAQ: INM) is a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs. The company today announced that Jerry Griffin, VP of Sales and Marketing for InMed's subsidiary BayMedica LLC, a leading supplier of bioidentical rare cannabinoids to the health and wellness ("H&W") market, will be participating in a fireside chat with Water Tower Research on July 25, 2023, at 2:00 p.m. ET. The event is open for all investors with topics that include an overview of BayMedica, its competitive environment and upcoming catalysts, as well as the market dynamics of rare cannabinoids and their disruptive potential in the H&W sector. Interested parties should visit to register for the event.

To view the full press release, visit

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the manufacturing and clinical development of rare cannabinoids. InMed is a clinical stage company developing cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab and has recently announced an LOI to acquire a leading rare cannabinoid manufacturer.

Research and Technology

There are more than 100 rare cannabinoids found in only trace amounts in the cannabis plant, together making up less than 1% of the plant’s biomass. InMed is initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. Preclinical studies of CBN demonstrated an excellent safety profile and showed CBN has potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD).

Evidence suggests there may be great therapeutic potential in rare cannabinoids. Each has a specific chemical structure, and different cannabinoids have been observed to have distinct physiological properties in humans, including therapeutic potential for specific diseases as well as unique safety profiles. CBN is the active pharmaceutical ingredient (API) in InMed’s two lead programs for dermatological and ocular diseases.

InMed’s most advanced compound, INM-755, is a CBN topical cream under clinical development for the treatment of epidermolysis bullosa, a severe genetic skin disorder. To date, INM-755 has been evaluated in two Phase 1 clinical trials in healthy volunteers. InMed has filed Clinical Trial Applications in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. Responses from the National Competent Authorities and Ethics Committees are expected throughout the summer of 2021.

InMed is also involved in developing INM-088, an ocular CBN formulation being researched for the treatment of glaucoma, the second leading cause of blindness in the developed world. InMed is currently evaluating several formulations to deliver CBN into the eye to address issues of dosing frequency, side effects and treatment penetration. INM-088 is being designed for topical delivery to the eye. This localized delivery results in very little drug being absorbed or migrating into the bloodstream, thus minimizing potential adverse side effects. INM-088 shows promise to reduce intraocular pressure and provide neuroprotection of the eye.


The limited availability of rare cannabinoids like CBN makes them economically impractical to extract directly from the plant for pharmaceutical use. InMed is developing IntegraSyn, a cannabinoid synthesis manufacturing system to create rare cannabinoids in the lab that are bioidentical to the compounds derived from the cannabis plant. IntegraSyn uses multiple standard pharmaceutical processes and has achieved a cannabinoid yield of 5 grams per liter, surpassing commercial viability and significantly exceeding currently reported industry yields. InMed is now focusing on manufacturing scale-up to larger batch sizes while continuing process optimization, targeting increased cannabinoid yield and further reducing overall cost of goods.

BayMedica Inc. Acquisition

On June 29, 2021, InMed announced it had entered into a non-binding letter of intent to acquire BayMedica Inc., a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.

As noted in the news release, BayMedica is a revenue-stage biotechnology company leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications. BayMedica is currently commercializing the rare cannabinoid CBC (cannabichromene) as a B2B supplier to distributors and manufacturers marketing products in the health and wellness sector. BayMedica is planning additional rare cannabinoid launches for the coming year.

Pursuant to the indicative terms of the LOI, InMed and BayMedica intend to negotiate and enter into a definitive agreement under which InMed would acquire 100% of BayMedica in exchange for 1.6 million InMed common shares to be issued to BayMedica’s equity and convertible debt holders, with any such issued InMed common shares being subject to a six-month contractual hold period.

Market Outlook

There is a rapidly growing demand for rare cannabinoids. However, their low natural concentration makes traditional harvesting of these compounds cost prohibitive. Biosynthesis allows production of rare cannabinoids in the lab that are bioidentical to compounds found in nature, with significantly higher yields which reduce costs. Biosynthesis can produce pharmaceutical-grade, bioidentical, THC-free compounds at a cost that’s 70 to 90 percent less than wholesale prices of naturally harvested rare cannabinoids.

Cannabinoid-based pharmaceuticals are expected to overtake the market as rare cannabinoids become less expensive and more available. According to Statista, the value of the consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029, with cannabinoid-based pharmaceuticals used to treat health conditions including pain, respiratory conditions, autoimmune conditions and more.

Management Team

Eric A. Adams has been CEO and president of InMed since June 2016. He has more than 25 years of experience in establishing corporate entities, capital formation, global market development, mergers and acquisitions, licensing and corporate governance. He previously served as CEO at enGene Inc. Prior to enGene, he held senior positions in global market development with QLT Inc. (Vancouver), Advanced Tissue Sciences Inc. (La Jolla, CA), Abbott Laboratories (Chicago, IL) and Fresenius AG (Germany).

Bruce S. Colwill is InMed’s CFO. He has more than 25 years of financial leadership experience in public and private companies. Prior to InMed, he served as CFO of General Fusion Inc., a private clean energy company. He was also CFO at Entrée Resources Inc., a mineral exploration company, from 2011 to 2016. He has held CFO roles at Neuromed Pharmaceuticals Ltd., Response Biomedical Corp, Forbes Medi-Tech Inc. and Euronet Worldwide Inc.

Alexandra D.J. Mancini is Senior Vice President, Clinical and Regulatory Affairs at InMed. She has more than 30 years of global biopharmaceutical research and development experience. She has been an executive with numerous biotech companies, including senior vice president of Clinical and Regulatory Affairs at Sirius Genomics; senior vice president of Clinical and Regulatory Affairs at INEX Pharmaceuticals; and vice president of Regulatory Affairs at QLT Inc.

Eric C. Hsu is Senior Vice President, Pre-Clinical Research and Development at InMed. He joined InMed with more than 18 years of scientific leadership experience in the field of gene therapy. He has held various positions within enGene Inc., including vice president of Research and vice president of Scientific Affairs and Operations. He received his Doctorate from the Department of Medical Biophysics at the University of Toronto.

Michael Woudenberg is Vice President, Chemistry, Manufacturing and Controls at InMed. He has more than 20 years of successful drug development, process engineering, GMP manufacturing and leadership experience. He has held positions with 3M, Cardiome Pharma, Arbutus Biopharma and, most recently, was Managing Director of Phyton Biotech LLC.

InMed Pharmaceuticals Inc. (INM), closed Friday's trading session at $1.05, up 6.0499%, on 67,185 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.90/$19.50.

Recent News

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF)

The QualityStocks Daily Newsletter would like to spotlight Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF).

Reflex (CSE: RFLX) (OTCQB: RFLXF) (FWB: HF2), a British Columbia-based strategic minerals company focused on locating and developing economic properties within the advanced materials space, has centered its corporate mission around catering to the burgeoning need for natural graphite supply through its flagship asset the Ruby Graphite Project. "One of a handful of companies comprising the western natural graphite supply chain, Reflex Advanced Material's flagship project is a past producing graphite mine in southwest Montana, which produced upwards of 2,400 tons of graphite between 1902 and 1948, as well as the Ontario-based Zig Zag Lithium Property, encompassing eight mining claims across 2,710 hectares," a recent article reads. "As a result, and in a sector characterized by opaque pricing and long-term bilateral off-take agreements between producers and consumers, Reflex Advanced Materials recently revealed that it has begun the qualification process with prospective North American customers, putting the company years ahead of its peers within the lengthy graphite sales cycle. With an upcoming drill program scheduled to kick off in the summer of 2023 at its Ruby Graphite project, alongside two product development and material research partnerships currently underway in an effort to help the company diversify its risk profile and improve margins, Reflex Advanced Materials is aiming to emerge as one of the biggest beneficiaries of the global push towards an electric vehicle-powered future."

To view the full article, visit

Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) is a strategic minerals company focused on locating and developing economic properties in the strategic metals and advanced materials space. The company aims to improve domestic specialty mineral infrastructure efficiencies to meet surging national demand from North American manufacturers, effectively positioning itself as one of the only North American suppliers of high purity natural graphite for hi-tech applications.

Reflex Advanced Materials is based in Vancouver, British Columbia. Its project portfolio includes the Ruby Graphite Deposit in Montana and the ZigZag Lithium Property in Ontario.


Ruby Graphite Project

Located in a mining-friendly jurisdiction in southwest Montana, the Ruby Graphite Deposit is a low cost, rapid re-entry opportunity that produced roughly 2,400 tons of graphite from 1902 to 1948. Reflex Advanced Materials holds mining rights for 755 hectares at the Ruby Graphite Project, with 96 federal lode mining claims. Recent samples assay at 95.8% to 98.4% total carbon.

The site is notable as the only combined U.S. graphite flake and vein graphite source. Vein graphite is ideal for energy storage applications, because it requires fewer steps to achieve purity than synthetic alternatives and is therefore far less environmentally damaging. This is expected to play a key role in the project’s development as demand for electric vehicles continues to surge.

In March 2023, the company announced its submittal of permit applications to the Bureau of Land Management in respect of its exploration of the Ruby Graphite Project. Its initial drill program, expected to take place in the summer of 2023, includes plans for 3,500 total meters of drilling, cored to an average depth of 130 meters. The targets for this drill program have been identified using historical data from original mine operations and data gathered for the initial 43-101 technical report on the project, dated January 31, 2023.

ZigZag Lithium Property

Located in the Thunder Bay Mining Division of Ontario, the ZigZag Lithium Property consists of eight mining claims spanning roughly 2,710 hectares. Mineralization at the property, most notably lithium, is based in pegmatite dikes and concentrated in spodumene crystals, which are consistent throughout the entire unit.

Spodumene is readily observable in outcrops and in drill cores, with crystal sizes ranging from 3-15cm, on average.

Reflex Advanced Materials and American Energy Technologies Company Metallurgical Partnership

Reflex Advanced Materials has entered into a material processing agreement with American Energy Technologies Co., which is based in Arlington Heights, Illinois, to conduct metallurgical testwork with the goal of creating a technical support data package for Reflex’s target customer base, U.S. Federal agencies and qualification programs with hi-tech customers in the battery and battery storage business.

The resulting coated, spherionized, purified graphite (CSPG) material that is expected to be created from the aforementioned tests will be used to provide potential customers of CSPG with samples so that they can begin the material qualification process.

Market Opportunity

Graphite is an ideal battery anode and has dominated the market since the proliferation of lithium-ion batteries. Despite this demand, there is currently no significant production of lithium-ion battery anode material in North America.

Instead, most graphite sold in North America today is sourced from Chinese producers. U.S. President Joe Biden highlighted this sourcing disparity in a 2022 address:

“The United Stated depends on unreliable foreign sources for many of the strategic and critical materials necessary for the clean energy transition – such as lithium, nickel, cobalt, graphite and manganese for large-capacity batteries,” he said. “Demand for such materials is projected to increase exponentially as the world transitions to a clean energy economy.”

The U.S. Department of Energy is in the process of awarding $2.8 billion to expand domestic manufacturing of batteries for electric vehicles and combat this foreign dependency. Reflex Advanced Materials has identified its Ruby Graphite Project as a prime candidate for U.S.-sponsored initiatives due to the rarity and scarcity of natural graphite deposits in the country.

Processing graphite domestically in the U.S. is expected to provide Reflex Advanced Materials a competitive advantage as manufacturers begin to seek out American supply in the face of increased diplomatic tension. This is critical, as a rise in anode demand is expected to fuel a shortage of 8 million tonnes of graphite by 2040. World Bank Group projects 494% growth in total graphite demand by 2050.

Leadership Team

Paul Gorman is the CEO and a Director of Reflex Advanced Materials. He brings to the company over 25 years of experience in junior mining finance, public listings, viability assessment and operational rationalization. For 18 years, Mr. Gorman served as president and managing partner of Riverbank Capital, where he played an instrumental role in raising more than $85 million for small-cap companies. In 2008, he funded Industrial Minerals Inc. (later Northern Graphite) and served in an advisory role for four other graphite companies, contributing significantly to the revitalization of the junior graphite space in North America. Mr. Gorman founded Mega Graphite Inc. in 2009 and has served as chief executive for three other companies.

Tasheel Jeerh, CPA, is the company’s CFO. He is a finance and accounting professional with over a decade of experience spanning both public and private sectors. Prior to joining Reflex Advanced Materials, Mr. Jeerh played a pivotal role in the growth of a private upstream oil and gas firm, dealing with over $2 billion in M&A activity and $1 billion in financing activities. He gained his designation at PricewaterhouseCoopers, where he worked as a manager in the assurance practice.

Greg Bell is Project Manager for Reflex Advanced Materials. He is a multi-disciplined engineering management professional with more than 40 years of experience in the natural resources sector. Mr. Bell has successfully built and managed several start-up operations in various capacities. He has been active in graphite and lithium exploration for the past seven years.

Christopher W. Hill leads the company’s Corporate Development initiatives. He is an investor and entrepreneur with over a decade of experience in the capital markets. Mr. Hill began his career as an investment advisor and then began to consult and advise private companies on their paths to becoming publicly traded. He specializes in corporate development and strategic financing utilizing his large network in the capital markets.

Reflex Advanced Materials Corp. (RFLXF), closed Friday's trading session at $0.309, up 1.1788%, on 70,523 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.15/$0.765.

Recent News

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services (OTCQB: SHRG), a company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies, recently launched its new Shared Services Platform. "The announcement signals the company's strategic move to offer a variety of services specifically designed to support companies in the direct-selling industry, a space in which SHRG has proven expertise… The company has applied its background and experience with direct selling to design a wide range of services that will support an array of companies, from startups to seasoned organizations. These cost-effective, proven solutions include financial and accounting services, global fulfillment and logistics, back-office platforms and mobile applications, commercial insurance services, merchant processing, inventory financing and equity funding, and event planning and merchandising. In preparing for this significant offering, SHRG has partnered with other industry experts to ensure the platform delivers best-of-class services that meet the expectations of clients and customers," a recent article reads. "At Sharing Services, our goal is to provide cost-effective, enterprise-level solutions that address our customers' key operating needs," Sharing Services CEO John "JT" Thatch is quoted as saying. "Our platform of services incorporates the absolute highest-caliber solutions for the companies we partner with."

To view the full article, visit

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

469.304.9400 x 201

Sharing Services Global Corporation (SHRG), closed the day's trading session at $1.01, up 23.17%, on 276,351 volume with 217 trades. The average volume for the last 3 months is 279,074 and the stock's 52-week low/high is $0.27/$2.54.

Recent News

Fintech Ecosystem Development Corp. (NASDAQ: FEXD)

The QualityStocks Daily Newsletter would like to spotlight Progressive Care Inc. (OTCQB: FEXD).

Digital money is replacing physical cash and further supporting the growth of a growing cashless society driven by the pandemic and other factors

FEXD supports the United Nations' Sustainable Development Goals of reducing cross-border transaction costs from 7 percent to 3 percent

FEXD plans to offer a diverse portfolio of products and services to consumers and businesses in the United States, South Asia, East Asia, Africa, Europe, and Latin America

Financial technology, more commonly referred to as fintech, fuels economic growth and reduces inequality, poverty, and informality in underdeveloped companies. For impoverished people and small businesses without access to financial services as simple as a bank account, fintech creates opportunities and the ability to send and receive payments securely and access to savings, credit, and insurance products. Fintech Ecosystem Development (NASDAQ: FEXD), a special purpose acquisition company ("SPAC"), was formed with the mission of creating and growing a global financial services ecosystem to address unmet mobile money needs in developing and industrialized countries and markets. Fintech Ecosystem Development Corp. (NASDAQ: FEXD), a company working to stay ahead of fintech innovation, is guided by the vision to develop financial service applications that allow its customers to move money easily whilst making it more affordable for people to conduct transactions without touching cash. "The company believes this is a moment in history when mobile money services are needed in a world moving to digital money and mobile transactions that are seamless across international borders. And with cryptocurrencies conveniently facilitating cross-border mobile transactions, even for users whose governments have restricted the movement of money out of their countries, FEXD's focus on this advanced financial technology appears strategic," explains a recent article. "‘We're committed to supporting the progress of developing countries and cultures. We have a keen understanding of market needs in many regions of the world where cellphones are in wide use but mobile money services are not yet available,' reads FEXD's website. By channeling its resources and attention into these markets, the company hopes to ‘ensure humanity has a path forward from an unhygienic cash system; to reduce poverty; improve lives of the unbanked; offer security and saving options for migrant workers;' and more."

To view the full article, visit

Fintech Ecosystem Development Corp. (NASDAQ: FEXD) is a special purpose acquisition company (SPAC) formed for the purpose of effecting one or more business combinations with an intent to focus on the financial technology sector.

The company’s mission is to create and grow a global financial services ecosystem to address unmet mobile money needs in developing and industrialized countries and markets. FEXD plans to achieve this by acquiring and merging with financial technology pioneers that have the potential to help establish its global fintech ecosystem, and by continuing the development of proprietary technologies and applications to keep the company at the forefront of the cashless society market.

Digital money is replacing physical cash. Consumers can buy products and services from anywhere in the world and make payments across borders. Parents can send money to students studying in other countries. Migrant workers are sending money to families in developing nations. Rural villagers without banks can send and receive money using their smartphones. FEXD is developing mobile transaction platforms, applications and services that are helping to implement these changes.

The company plans to offer a diverse portfolio of products and services to consumers and businesses in the United States, South Asia, East Asia, Africa, Europe and Latin America. Its growth strategy includes acquisition, innovation and market development.

FEXD is a Delaware corporation based in Collegeville, Pennsylvania. The company was launched in May 2021 by a management team led by Dr. Saiful Khandaker that has extensive experience in developing and managing financial service platforms and applications, primarily in the mobile money sector. FEXD is sponsored by Revofast LLC.

Acquisition Targets

In September 2022, FEXD announced definitive agreements for business combinations with Rana Financial Inc., a Georgia corporation, and Mobitech International LLC (dba Afinoz), a limited liability company organized in the United Arab Emirates. The agreements call for Rana and Afinoz to become wholly owned subsidiaries of FEXD, with the combined company expected to continue trading on the Nasdaq under existing ticker symbol ‘FEXD’. The mergers are expected to close in Q2 2023.

Rana Financial

Rana Financial is a licensed money transfer company founded in 2009. Rana provides fast and affordable online and mobile transfer of funds between the U.S. and Latin America. Rana has been providing money transfer services in the U.S. market for 13 years and has 30,000 active users. Rana’s money transfer business grew to 200,000 transactions in 2021. The merger agreement values Rana at an implied $78 million enterprise value.

Mobitech International LLC

Mobitech International LLC (dba Afinoz) is an artificial intelligence-enabled digital lending platform used by India’s leading banks, non-banking financial companies and fintech loan providers. Afinoz’s fintech platform supports enterprises making loans primarily to middle- and working-class borrowers via its website or through its mobile phone application. Afinoz’s platform makes loans available and affordable to millions of Indian workers and unbanked users by providing access at a low cost. Afinoz’s platform has more than 50 lending partners, and its database of registered users in India includes more than two million individuals. The merger agreement values Afinoz at an implied $120 million enterprise value.

Market Opportunity

According to analysis by global market research firm Mordor Intelligence, the worldwide financial technology market is valued at approximately $194 billion in 2023 and is projected to grow to nearly $500 billion by 2028, representing a CAGR of 18.97% for the forecast period. According to the report, various financial crises and the COVID-19 pandemic have fueled consumer adoption of, and investor interest in, fintech over the past several years.

Management Team

Dr. Saiful Khandaker is Founder, CEO and President of FEXD. He is Group CEO and founder of FAMA Holdings Inc., a global developer of fintech platforms, applications and services based in the U.S. with offices in the U.K., India, Bangladesh and Zambia. He is currently leading the development of the FAMACASH™ network, a global fintech ecosystem to provide fast, affordable mobile money services in underserved countries such as Bangladesh. Before founding FAMA, Dr. Khandaker spent more than two decades leading the development of software solutions for Fortune 100 companies and startups. He also helped numerous clients modernize their fintech services as Chief Technology Officer at Mi3. He holds a Doctor of Management in Organizational Leadership, a Master of Science in Technology Management, and a Bachelor of Science in Computer Information Systems.

Jenny Junkeer is CFO at FEXD. She is a Chartered Accountant with over 17 years of experience. As CEO of Junkeer New Era Consulting, she leads a team specializing in helping companies launch and optimize business operations in fast-changing industries. She has extensive experience helping organizations scale operations to maximize value. She is an Adjunct Association Professor at Deakin University in Australia, a board member of the Global Health Initiative Foundation, and Director of Implementation at ConnectCV. She holds a Bachelor of Commerce Degree (Honors) from Monash University.

FingerMotion Inc. (FEXD), closed Friday's trading session at $10.58, even for the day, on 2,005 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $10.01/$11.00.

Recent News

Advanced Container Technologies Inc. (OTC: ACTX)

The QualityStocks Daily Newsletter would like to spotlight Advanced Container Technologies Inc. (OTC: ACTX).

Social-equity founders in America's state-level cannabis industry are facing a myriad of challenges despite enjoying purported industry support. Social equity refers to a set of policies designed to give people who were disproportionately affected by the drug war a leg up in the cannabis industry. These policies are meant to give communities that endured over policing and harsh sentencing for decades due to prohibitionist cannabis laws a chance to benefit from a drug that was once used to persecute them. However, despite the good intentions behind social-equity provisions, founders from communities of color and lower-income communities still struggle to carve a space for themselves in the lucrative marijuana sector. As these challenges are gradually addressed, equity businesses could thrive and create more business opportunities for ancillary entities such as Advanced Container Technologies Inc. (OTC: ACTX) that sell cultivation equipment and other products designed to meet the needs of marijuana-touching businesses.

Advanced Container Technologies Inc. (OTC: ACTX) is in the business of selling and distributing self-contained, automated, indoor “micro-farms” called Grow Pods, along with related equipment and supplies. Additionally, the company designs and sells patented proprietary medical-grade plastic containers, known as the Medtainer®, that store and grind pharmaceuticals, herbs, teas and other solids or liquids.

ACTX is the leading distributor of Grow Pods. With a controlled environment, food and herbs can be grown without pesticides, harmful chemicals or risk of pathogen contamination, and with low energy consumption. Restaurants, grocery stores, non-profits, MSOs and entrepreneurs can use Grow Pods to ensure a fresh supply of ultra-clean produce year-round.

The company entered the Grow Pod business in October 2020 with its acquisition of all shares of Advanced Container Technologies Inc., a California corporation. As of February 28, 2022, ACTX is exploring the acquisition of the assets and the assumption of some or all of the liabilities of GP Solutions Inc., the developer and manufacturer of Grow Pods, for which ACTX is currently the sole U.S. distributor.

Because Grow Pods can be located almost anywhere, produce can be grown closer to the point of consumption and harvested at its peak, providing nutritious fruits and vegetables where needed. Indoor micro-farms, utilizing a practice known as vertical farming, have attracted the attention of governments and universities, which are now promoting vertical farming as a way to combat food insecurity and inequities.

The United States Department of Agriculture (USDA) has stated that vertical farming “is no longer a futuristic concept.” The department is enthusiastic about vertical farming, particularly those utilizing repurposed shipping containers, such as Grow Pods. Arizona State University reports that vertical farming reduces water use by 90 percent compared to conventional farming but produces 10 times the crop yield.


Grow Pods

One of the company’s main business units is focused on selling advanced, self-contained hydroponic containers called Grow Pods. These unique and innovative automated systems are essentially micro-farms that can be placed virtually anywhere and, with their controlled and specially filtered environment, allow cultivation of a wide variety of crops, 365 days a year. The Grow Pod controlled environment offers major advantages for the production of high-value crops. The ability to grow year-round and the ability to cultivate in a smaller footprint using less water and power are some of the primary advantages of the system. Grow Pods offer constant temperature, humidity and airflow control, as well as automated watering and lighting schedules for optimal growth and minimal labor requirements, regardless of crop.


ACTX meets the needs of the pharmaceutical and medical markets, including the cannabis and hemp industries, with patented packaging systems. The company designs, customizes, brands and sells proprietary medical grade plastic containers that can store pharmaceuticals, herbs, teas and other solids or liquids, with a special built-in feature that can grind solids and shred herbs. The company’s flagship container product is the patented Medtainer®, a child resistant, medical-grade herb container and grinder that is water-tight, air-tight and smell proof. Packaging in the cannabis industry is critical, with numerous stringent regulations about how cannabis products must be packaged and labeled. ACTX also offers custom-branded, compliant vacuum seal bags and other retail container solutions.

Equipment and Supplies

ACTX markets and sells two principal products: Grow Pods, which are specially modified insulated shipping containers manufactured by GP Solutions Inc., in which plants, herbs and spices may be grown hydroponically in a controlled environment, and Medtainers®, which may be used to store pharmaceuticals, herbs, teas and other solids or liquids and can grind solids and shred herbs. The company also markets and sells various products related to Grow Pods and the Medtainer®, as well as providing private labeling and branding services for purchasers of Medtainers® and certain related products.

GP Solutions manufactures and sells other products, such as humidity controllers and LED lighting systems for vertical farming. The company’s specially designed lighting panels are programmed to emit the exact wavelength of light that each crop requires. The system has a daybreak-to-nightfall feature that gives plants the proper chromatic signals to grow rapidly and fruitfully. High efficiency LED light strips supply the crops with a red and blue light spectrum required for photosynthesis in the spectrum that plants need most.

Market Overview

The global vertical farming market is expected to reach $33.02 billion by 2030, according to a new report by Grand View Research. The market is forecast to expand at a CAGR of 25.5 percent from 2022 to 2030, according to Grand View. Escalating production of biopharmaceutical products, including cannabis, is anticipated to drive the market. The building-based segment of the market is expected to register a significant CAGR of 27.8 percent over the projected period. In addition, the climate control segment is expected to see high growth.

The global cannabis packaging market is expected to reach $14.34 billion by 2028, according to analysis by Reports and Data. The analysis forecasts 1,700 percent growth in cannabis users by the end of 2026, with packaging likely observing a whopping 26.42 percent growth in the forecast period. There are significant barriers to entry in the cannabis packaging market, giving an advantage to companies already established in the sector. These barriers include developing a thorough knowledge of the myriad regulations that govern cannabis packaging (which differ in each state), and child-resistance requirements.

Management Team

Douglas P. Heldoorn is the Founder and Chairman of Advanced Container Technologies Inc. He also holds the positions of President, CEO and COO at the company. Mr. Heldoorn has served on the Board of Directors since its inception in 2013. He has also previously held the position of Executive General Manager at Nissan Motor Corp.

Jeffory A. Carlson is CFO and Treasurer of ACTX. Mr. Carlson has also served as the company’s Corporate Controller since 2014.

Advanced Container Technologies Inc. (OTC: ACTX), closed Friday's trading session at $0.21, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0141/$0.70.

Recent News

Electronic Servitor Publication Network Inc. (OTCQB: XESP)

The QualityStocks Daily Newsletter would like to spotlight Electronic Servitor Publication Network Inc. (OTCQB: XESP).

Electronic Servitor Publication Network (OTCQB: XESP), a growth-focused digital activation and engagement solutions innovator and provider targeting B2B companies, is at the forefront of the digital transformation that is taking over B2B markets. "XESP has positioned itself as the go-to company for clients looking for growth through optimizing their digital contact with target audiences in non-face-to-face situations. The company has developed a sophisticated technology stack that, coupled with its proven processes and workflows, provides real time data to client companies, enabling a dynamic and personalized connection between them and their target audiences," a recent article reads. "‘And in the end, it's all about growth,' said CEO Peter Hager in a recent interview with Proactive Investors. This is because XESP drives better interactions, facilitating better results for its clients. It also solves content management and optimization deficiencies in a fast-moving economy and market, thus guaranteeing its relevance. Moreover, XESP helps its customers preserve margins through efficiency… ‘Our Growth-as-a-Service Business model is focused on what is most important for our clients – producing results,' Hager continued."

To view the full article, visit

Electronic Servitor Publication Network Inc. (OTCQB: XESP) is a digital engagement company offering a managed service which provides digital activation and engagement solutions to companies that seek to optimize their growth. Its managed service is powered by a proven, proprietary technology – the Digital Engagement Engine™. This technology provides intelligent interaction management, dynamic content provisioning, and a logic-driven workflow, which creates digital experiences that accelerate an audience from awareness to action – driving growth.

Electronic Servitor Publication Network’s services are designed to drive growth for both established and developing organizations. Through the optimization of digital interactions within current and new communities, the Digital Engagement Engine™ ensures that client content is relevant, reaches the right audience, and connects with the intended person at the right time.

The company calls it ‘Growth as a Service’.

Client implementation is nearly effortless, since the solution is completely managed by the Electronic Servitor Publication Network team. This business model allows clients to focus on their brands, core product offerings, and content creation, while the company manages the technology and outcome.

The company is headquartered in Minneapolis, Minnesota.


Electronic Servitor Publication Network’s Digital Engagement Engine™ utilizes a combination of automation, unique data management, and a modern workflow built on a microservices architecture to achieve greater reach and lift. Using sophisticated data analysis and smart technology, the Digital Engagement Engine™ provides companies with the ability to maintain complete control of their content while creating meaningful relationships with new customers and revenue streams.

The Digital Engagement Engine™ isn’t just another marketing or technology tool; it’s a way to develop real connections with target markets.

Market Outlook

According to a report by, an award-winning market research firm, the global customer engagement solutions market was estimated at $19.3 billion in 2022 and is forecast to grow to $32.2 billion by 2027, achieving a CAGR of 10.8% during the forecast period.

The report notes that these engagement solutions are vital to companies seeking to widen their customer bases, reduce customer churn rates and increase customer retention. These perceived benefits of customer engagement solutions are likely to drive their growing adoption around the globe during the forecast period, according to the report.

Management Team

Peter Hager is President and CEO of Electronic Servitor. He joined the company from Pointward Inc., a medtech customer engagement agency that provided solutions to drive market entry, growth, and commercialization for Fortune 500 health care brands and medtech startups. He has founded and managed multiple technology, professional services and medtech organizations throughout his career. Mr. Hager holds a bachelor’s degree from Macalester College in St. Paul, Minnesota, with concentrations in economics and psychology.

Jim Kellogg is CFO of Electronic Servitor. He has served as the principal of J. Kellogg & Company Inc., a business and tax consultant, since 2005. He has provided legal support to clients’ business valuations, business interruption and divorce property valuations. He has worked as a professional tax adviser since 1983. Mr. Kellogg obtained his JD with emphasis on taxation from Western State University College of Law and was certified as a financial planner by the College for Financial Planning in 1990.

Thomas (Denny) Spruce, RPh, is COO of Electronic Servitor. He oversees company infrastructure, regulatory reporting, and strategic partner relationships, among other roles and responsibilities. He joined the company in March 2022 and, since that time, has implemented foundational support processes, developed contractual relationships with service providers, managed financial and regulatory reporting and overseen contract development and management with the legal team. Mr. Spruce obtained a BS in Pharmacy from the University of Arkansas.

Electronic Servitor Publication Network Inc. (XESP), closed Friday's trading session at $0.06, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.03/$0.2245.

Recent News


The QualityStocks Daily Newsletter would like to spotlight NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW).

Online retailers on Amazon reported record sales numbers during the recent Prime Day summer sales event, selling more than $12.7 billion worth of product in two days and setting an eCommerce record. Held every year, the summer sale is a members-only event that grants customers exclusive discounts on thousands of different products across nearly every category on the platform. Amazon-only products such as Echo smart speakers, Kindles, Fire Tablets and Fire TV Sticks offered the highest discounts, and even subscription services such as Amazon Music Unlimited were on sale. The event ran from July 11 to 12, 2023, and offered lightning deals, deals of the day, and invite-only deals to Amazon Prime members. These impressive sales figures by Amazon show that as more companies such as NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW) focus on expansion in the ecommerce space, the only way for ecommerce to go over the coming years is up.

NextPlat Corp. (NASDAQ: NXPL) (NASDAQ: NXPLW), a next generation e-commerce platform, was created with vision and purpose to capitalize on high growth sectors and global markets. The company collaborates with businesses – large and small – to simplify and accelerate online commerce and uniquely enables customers and partners to optimize their e-commerce reach, presence and revenue. NextPlat recently launched a new e-commerce development program to provide American businesses with easy access to the massive Chinese consumer market.

Current Initiatives

NextPlat provides cutting edge technology in an advanced e-commerce ecosystem. The company is actively expanding its global network of online storefronts serving thousands of consumers, enterprises and governments. The company also has developed a next generation platform built for Web3 that enables the creation and sale of digital assets, as well as optimizing e-commerce transactions and business building activities. The company’s current initiatives include:

  • E-Commerce Development Program – In April 2023, NextPlat announced it had entered into a merchant sourcing agreement with Singapore E-Commerce Private Limited (“Alibaba”) and its Tmall Global e-commerce platform whereby the two companies will collaborate to increase the sale of products produced and sold by American companies to the multi-trillion-dollar Chinese consumer market. Alibaba’s Tmall Global e-commerce platform will provide NextPlat customers a turn-key solution through which products can be sold to the Chinese consumer market. The launch of the Florida E-Commerce Development Program is the first in a series of new NextPlat programs designed to assist U.S. businesses in expanding their online sales capabilities to reach new international customers in the Chinese market. NextPlat intends to rapidly expand this unique e-commerce development opportunity to businesses throughout the United States and all of North America, as well as Central and South America. The new development program features NextPlat’s turnkey global e-commerce solution for customers and leverages NextPlat’s relationships with key partners, including Tmall Global, China’s largest cross-border B2C online marketplace.
  • Progressive Care Inc. – In August 2022, NextPlat completed a strategic $7 million investment in Progressive Care Inc. (OTCQB: RXMD), a personalized health care services and technology company. In a news release announcing the investment, NextPlat CEO Charles M. Fernandez noted that the company is “committed to harnessing the power of digital technologies to capitalize on the ongoing digital transformation of Progressive Care and the entire health care industry.” NextPlat intends to accelerate Progressive Care’s digital health care transformation with the launch of a new e-commerce platform for health care products later this year.
  • NextPlat NFT Platform – Building on its existing e-commerce initiatives, NextPlat is working to bridge the gap between tangible and digital e-commerce marketplaces by incorporating burgeoning Web3 technologies. The company intends to launch a fully integrated NFT platform in the coming months that will enable brands to create, manage and authenticate digital assets while serving as a new source of revenue for NextPlat. Through this model, the company will receive a portion of the revenue generated from branded NFT drops, as well as subsequent secondary market transactions.
  • Global Telesat Communications and Orbital SatCom Corp. – Targeting both domestic and international markets, NextPlat’s subsidiaries leverage partnerships with major e-commerce platforms such as Amazon, Alibaba, eBay and Walmart to serve a growing base that includes more than 50,000 corporate, governmental and individual customers. In total, the brands market more than 10,000 individual products, with a focus on satellite-based connectivity solutions. In addition to exploring accretive M&A opportunities, NextPlat aims to diversify its range of products and broaden its geographic footprint moving forward in an effort to better capitalize on the tremendous growth potential in the United States, Europe and Asia.

“Our goal for 2023 and beyond is to leverage our improved operational capabilities and enhanced leadership team as we expand our offerings in communications and connectivity into the high-growth health care market where we intend to launch an array of innovative new offerings,” Fernandez said in a March 2023 news release detailing the company’s record top-line performance. “Although there remain supply chain headwinds and the challenge of global inflation, we are confident that we have the right combination of market-tested expertise, technology and partnerships that will enable us to bring the power of e-commerce to more customers, brands and industries in the United States and abroad.”

Market Opportunity

The rapid growth of e-commerce over the last decade is expected to continue for the foreseeable future. According to data published by Forbes, roughly 20.8% of all retail purchases are expected to take place online in 2023, accounting for total sales of $6.31 trillion worldwide. It total, e-commerce sales are expected to grow by 10.4% YoY in 2023, accounting for a whopping 24% of all retail purchases by 2026.

For NextPlat, existing partnerships in the industry could be key to capitalizing on this growth. The Forbes report indicates that Amazon accounts for roughly 38.7% of e-commerce sales, while sites like Walmart, eBay and Alibaba round out the list of most visited e-commerce websites. Alibaba is especially interesting due to NextPlat’s recent strategic merchant sourcing agreement with Tmall Global. The Chinese market is “mammoth,” as a recent Alizila report noted. The country’s annual online retail sales of physical goods have nearly doubled in the last five years, reaching approximately 13.8 trillion yuan in 2022, which is nearly $2 trillion USD.

The health care portion of the e-commerce market is generating particularly bullish forecasts, bolstered by the continued adoption of the 340B Drug Pricing Program in the U.S., which requires most drug manufacturers to provide outpatient drugs to covered entities at significantly reduced prices. Industry reports suggest that the global health care e-commerce market will expand at a compound annual growth rate of 16.8% from 2022 to 2030, climbing to a value of more than $1.37 trillion by the end of the forecast period.

Management Team

Charles M. Fernandez, CEO, Executive Chairman and Director of NextPlat, has over three decades of experience in identifying profitable start-up and dislocation opportunities, building significant value and executing exit strategies as an entrepreneur and global investor. Successful across multiple sectors, Fortune Magazine actually labeled Fernandez ‘a restructuring whiz’. As President of Fairholme Capital Management, which he joined in 2008, Mr. Fernandez co-managed all three Fairholme funds and brought in a $2 billion gain for shareholders. Throughout his impressive career, he has participated in more than 100 significant mergers, acquisitions and product development projects across multiple industries. Mr. Fernandez was the founder, Chairman and CEO of eApeiron Solutions LLC, a brand protection and e-commerce company in partnership with Alibaba (NYSE: BABA) and Eastman Kodak (NYSE: KODK), which was successfully sold to Smartrac, a unit of Avery Dennison Corp. (NYSE: AVY).

Rodney Barreto is Chairman and CEO of the Barreto Group and Director of Nextplat. Mr. Barreto’s business career spans over 35 years, including his role at the Barreto Group and, earlier, as the founding partner of Floridian Partners LLC, a corporate and public affairs consulting firm recognized by policy makers as one of the top in its industry in Florida. He chaired the Super Bowl Host Committee in 2007, 2010 and 2020, helping to raise more than $100 million for the success of Miami Super Bowls. As a philanthropist and conservationist, Mr. Barreto is also a three-time appointee to the Florida Fish and Wildlife Conservation Commission, where he has served for over 10 years including holding the title of Chairman eight times. He has twice chaired the Annual U.S. Conference of Mayors, was Chairman of the 1999 Breeder’s Cup Championship held in South Florida and was the Chairman of the 1999 Sister Cities International Convention in Miami. Currently, Mr. Barreto is the Membership Chairman of the Florida Council of 100, and a member of the Boards of Fairchild Tropical Botanic Garden, the Baptist Health South Florida Giving Society, the Bonefish and Tarpon Trust, the Guy Harvey Ocean Foundation, and a member of Miami Dade County Schools Superintendent Carvalho’s Business Advisory Council. Prior to his career in public affairs and real estate, Mr. Barreto was a City of Miami police officer and is a member of the Florida Highway Patrol Advisory Council.

NextPlat Corp. (NXPL), closed Friday's trading session at $2.32, off by 6.0729%, on 5,010 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.2115/$4.26.

Recent News

Knightscope, Inc. (NASDAQ: KSCP)

The QualityStocks Daily Newsletter would like to spotlight Knightscope, Inc. (NASDAQ: KSCP).

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots ("ASRs") and blue light emergency communication systems, has announced that a large, family-owned and operated dining company with over 2,500 locations (primarily in the U.S.) signed a contract for its K5 ASR service. The K5 will be deployed to patrol the company's corporate offices in Southern California to enhance employee safety at the campus while elevating the visitor experience.

The announcement reads, "Visits to open campuses are enjoyable and even motivating with the average American corporate employee spending a third of their waking hours inside of their company's campus. As outlined in Knightscope's 5-Step Recommendation for Corporate Campuses, security begins with a well-defined perimeter. And a good, proactive safety program is enhanced with Knightscope's technologies that help reduce vulnerabilities to many crimes, creating a safe and effective working environment."

To view the full press release, visit

Knightscope, Inc. (NASDAQ: KSCP), founded in 2013 and based in Mountain View, California, is a leader in the development of autonomous security capabilities targeting to disrupt the $500 billion security industry. Knightscope’s technology uniquely combines self-driving technology, robotics, artificial intelligence and electric vehicles.

Knightscope designs and builds Autonomous Security Robots (ASRs) that provide 24/7/365 security to the places you live, work, visit and study. The company’s client list covers public institutions and commercial business operations, including multiple Fortune 1000 companies to date. These ASRs have been proven to enhance safety at hospitals, logistics facilities, manufacturing plants, schools and corporations. ASRs act as highly cost-effective complementary systems to traditional security and law enforcement officials, providing an additional advantage by continuing to offer uninterrupted patrolling capabilities across the country.

The company’s ASRs have assisted in the arrest of suspects involved in crimes ranging from armed robbery to hit-and-runs. Their machine-embedded thermal scanning capability even aided in preventing the breakout of a major fire. You can learn more about the crime fighting wins at

The company has achieved several milestones since its creation in 2013, including:

  • Establishing itself in a 15,000-square-foot facility located in Mountain View, California, in the heart of Silicon Valley, where Knightscope designs, engineers and builds its technology (Made in the USA)
  • Operating for more than 1 million hours in the field and securing contracts across five time zones, from Hawaii to Rhode Island
  • Raising over $100 million since inception to build its technology from scratch and generating over $13 million in lifetime revenue, validating both the market opportunity and the technology

Growth Capital & Proposed Nasdaq Listing

With backing from more than 28,000 investors and four major corporations and over $100 million raised since inception, Knightscope is poised to be an industry leader in the future of public safety and security.

On December 1, 2021, Knightscope announced the commencement of an offering of up to $40 million of its Class A common stock, with shares to be listed immediately following closing on the Nasdaq Global Market under the ticker symbol ‘KSCP’. The offering is for up to 4 million shares priced at $10 per share. Learn more at

Company Mission – Reimagining Public Safety

Knightscope’s long-term vision has an eye on the greater good. The company’s mission is to make the United States of America the safest nation in the world while supporting the 2+ million law enforcement and security professionals across the country.

Crime has an estimated negative economic impact in excess of $2 trillion annually. As crime is reduced, positive impacts will likely be realized across several aspects of society, including housing, financial markets, insurance, municipal budgets, local business and safety in general.

Knightscope CEO William Santana Li was interviewed by Kevin O’Leary, more commonly known as Shark Tank’s Mr. Wonderful. When asked to explain how the benefits provided by the ASRs outrank a human doing the same job, Li said, “First, just the simple presence of a physical deterrent causes criminal behavior to change. Second, the machines are self-driving cars that patrol all around and recharge themselves. They also generate 90 terabytes of data per year. No human would ever be able to process that. The robots are intended to be eyes and ears for the humans, not a one-to-one replacement.”

The Knightscope solution to reduce crime combines the physical presence of ASRs, sometimes referred to as proprietary Autonomous Data Machines, with real-time onsite data collection and analysis. The ASRs are fitted with eye-level 360° cameras, thermal scanning, public address announcements and various other features that work in tandem with humans to provide law enforcement officers and security guards unprecedented situational awareness.

Those 90 terabytes of data are then formatted in a useable way, so law enforcement can leverage that information and execute their responsibilities more effectively.

Public Safety Innovation

The company’s recurring revenue business model is set up to mimic the recurring societal problem of crime, and it takes into consideration the fact that innovation in the security and public safety industry has been stagnant for decades. Because the traditional practices of the sector have remained unchanged for years, automation has potential to drive substantial cost savings – and significant improvement in capabilities.

Human security guards are one of both the largest expenses and the largest liabilities for companies. Knightscope’s robots are offered at an effective price of $3 to $9 per hour, compared with approximately $85 for an armed off-duty law enforcement officer and $15 to $35 for an unarmed security guard.

This innovation has the potential to drive considerable cost savings. Based on these estimates, manufacturing costs can be recovered as soon as the first year of operation.

Product Offerings

The company has nine patents and a framework of unique intellectual property. Knightscope currently offers a K1 stationary machine, a K3 indoor machine and a K5 outdoor machine. A K7 multi-terrain four-wheel version is in development.

The ASRs autonomously patrol client sites without the need for remote control, providing a visible, force multiplying, physical security presence to help protect assets, monitor changes in the area and deter crime. The data is accessible through the Knightscope Security Operations Center (KSOC), an intuitive, browser-based interface that enables security professionals to review events generated by the ASRs providing effectively ‘mobile smart eyes and ears’. Learn more at

The ASRs and the related technologies were developed ground up by the company and are Made in the USA.

The Robot Roadshow

Knightscope has created the ultimate hybrid physical and virtual event, bringing its Autonomous Security Robot technologies to cities across the country for interactive and in-person demonstrations.

Each roadshow landing is hosted virtually by a Knightscope expert, and visitors can interact directly with each of the company’s ASRs and see the Knightscope Security Operations Center (KSOC) user interface in action. Learn more at

Management Team

Chief Executive Officer William Santana Li is a veteran entrepreneur, a former executive at Ford Motor Company and the founder of GreenLeaf, a company that grew to be the world’s second-largest automotive recycler and is now part of LKQ Corporation (NASDAQ: LKQ).

Chief Client Officer Stacy Dean Stephens brings his experience as a former Dallas law enforcement officer, as well as his skills as a seasoned entrepreneur, to assist on the client acquisition side.

Chief Intelligence Officer Mercedes Soria is an award-winning technologist and former Deloitte software engineer.

Chief Design Officer Aaron Lehnhardt brings over two decades of two- and three-dimensional product and industrial design in modeling and VR to the table, on top of his experience as a senior designer at Ford Motor Company.

Chief Financial Officer Mallorie Burke is a seasoned financial executive and strategic advisor for both private and publicly traded technology companies with a successful track record of mergers & acquisitions, corporate growth and exit strategies, including public listings.

General Counsel Peter Weinberg leverages 30 years of diverse corporate counsel experience, spanning from startups to well-established companies, private and public. He has significant experience training personnel at all levels in critical areas to improve corporate compliance and productivity.

Knightscope, Inc. (NASDAQ: KSCP), closed Friday's trading session at $1.2, off by 26.3804%, on 8,876,266 volume. The average volume for the last 3 months is 8.876M and the stock's 52-week low/high is $0.36/$3.87.

Recent News

IGC Pharma Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight IGC Pharma Inc. (NYSE American: IGC).

Ukrainian members of parliament (MPs) have unanimously approved a measure to legalize marijuana, aiming to provide relief for war veterans struggling with physical and psychological trauma. The proposed bill, which permits the medical use of cannabis, effortlessly passed its initial reading, garnering support from 268 out of 344 legislators. Prior to becoming law, it must undergo a second reading in parliament and obtain the signature of President Volodymyr Zelensky. The significant backing for medical cannabis marks a notable shift in attitudes toward the substance since Russia's invasion of Ukraine. In 2021, a similar bill faced resounding defeat. Today, cannabis is recognized as a viable alternative to traditional prescription drugs for treating the extensive physical and mental injuries endured by thousands of civilians and soldiers during the war. Tymofiy Mylovanov, the director of the Kyiv School of Economics and an advisor to President Zelensky, affirmed, "Both veterans and the wounded rely on marijuana, and the legislature aims to legalize its usage." The medical use of marijuana is on the rise around the world. This could be the reason why we are seeing more enterprises such as IGC Pharma Inc. (NYSE American: IGC) taking steps to develop pharmacy-grade formulations from THC and other cannabinoids so that patients can have marijuana medicines that they can obtain through doctor prescriptions in the healthcare system.

IGC Pharma Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule ( As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products ( such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand ( that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.


IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.


The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

IGC Pharma Inc. (NYSE American: IGC), closed Friday's trading session at $0.338, off by 0.588235%, on 48,880 volume. The average volume for the last 3 months is 48,880 and the stock's 52-week low/high is $0.2785/$0.74.

Recent News

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF)

The QualityStocks Daily Newsletter would like to spotlight First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) .

First Tellurium (CSE: FTEL) (OTC: FSTTF) has announced that its president and CEO Tyrone Docherty will present live at the Metals and Mining Virtual Investor Conference, hosted by, that is taking place on July 26 and 27, 2023. Docherty's presentation is slated to begin at 11 a.m. PT on Wednesday, July 26. The company invites individual and institutional investors, as well as advisors and analysts, to attend in person or online at This will be a live, interactive online event where investors are invited to ask the company questions in real time. In addition, an archived webcast will be made available for attendees not able to join live on the day of the conference.

To view the full press release, visit

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) is committed to exploring for and providing essential and critical metals, including tellurium, gold, silver, copper and tungsten, for North American markets. This objective is anchored by the company’s Deer Horn tellurium-gold-silver-copper project in British Columbia, Canada, and further enhanced by its property option on the Klondike tellurium-gold prospect located in Colorado, USA.

First Tellurium’s unique business model is to generate revenue and value through mineral discovery, project development, project generation and cooperative access to untapped mineral regions in indigenous territory with sustainable exploration potential.

Through its exploration and partnerships with Fenix Advanced Materials, Cheona Metals and IRMA, First Tellurium strives to generate a measurable, beneficial social or environmental impact alongside a financial return. The company conducts a diversified search for metals, working in alliance with indigenous peoples, NGOs, governments and leading metals buyers. First Tellurium believes this is the future of mineral exploration — generating revenue by exploring responsibly and leveraging diverse partnerships.

First Tellurium proudly adheres to, and supports, the principles and rights set out in the United Nations Declaration on the Rights of Indigenous Peoples and, in particular, the fundamental proposition of free, prior and informed consent.

The company is headquartered in Vancouver, British Columbia.


Deer Horn Tellurium-Gold-Silver-Copper Project

Deer Horn is located on 51.33 square kilometers (km) in west-central British Columbia, 36 km south of the prolific Huckleberry copper-molybdenum mine and 135 km southwest of the community of Burns Lake. It is one of few significant tellurium discoveries outside Asia and includes a 2.4 km-long vein system of high-grade gold, silver and tellurium, as well as broader zones of bulk-tonnage gold, silver and tellurium mineralization. The company completed a positive Preliminary Economic Estimate and has began permitting for a 10,000-tonne bulk sample program to advance the project toward mine feasibility. It is North America’s only silver-gold-tellurium property with an NI 43-101 compliant tellurium resource, and it hosts a number of other mineralized targets and zone containing critical metals such as copper, tungsten and zinc.

First Tellurium owns 50% of the property, with an option to acquire up to a 75% interest. The company has engaged Dias Geophysical of Saskatoon, Saskatchewan, to conduct induced polarization (IP) geophysics on the Deer Horn Project in summer 2023. The program is designed to help develop drill targets for a subsequent drilling program.

Klondike Gold-Tellurium Project

The Klondike property is located in Saguache County, Colorado, southwest of Buena Vista in the state’s historical mining district. The company reports it has engaged Burgex Mining Consultants of Sandy, Utah, to stake additional claims around the Klondike property. The claims have been filed with the Bureau of Land Management.

Klondike demonstrates exceptional tellurium grades. Tellurium, used in high-efficiency cadmium telluride (Cd-Te) solar panels, next-generation lithium-ion batteries and thermoelectric devices to change heat into energy, is an essential element for the world’s transition to green energy.

The Klondike property was a top tellurium prospect owned previously by First Solar Inc., one of the world’s largest solar panel producers. First Solar terminated its worldwide raw materials exploration program in 2012 and sold the property to Colorado Klondike LLC, which optioned the project to First Tellurium. Colorado Klondike, led by First Solar’s former Exploration Manager in North America, is managing the upcoming exploration program.

The Colorado Geological Survey (CGS), in partnership with the Colorado School of Mines, reported on First Solar’s exploration at Klondike in 2015, noting: “Surface sampling by First Solar, Inc. in 2006 found very high tellurium grades of up to 3.3% (33,000 ppm), along with locally high gold grades. Tellurium grades at Klondike were the highest encountered in the company’s nationwide exploration program.”

Market Outlook

First Tellurium in spring 2023 referenced recent forecasts by the International Energy Agency (IEA) pointing to rapid growth in solar photovoltaic (solar PV) deployment worldwide. According to the agency, solar PV installations will generate more power by 2027 than any other energy source, including coal, natural gas and hydro. To meet this demand, consumption of both silver and tellurium, key components of solar panels, is expected to surge in coming years.

Chen Lin, founder of Lin Asset Management, has written in his investment newsletter for clients that solar PV is now the largest industrial usage of silver. He said that in 2022 solar PV production used about 12% of total silver demand, or about 120 million ounces of silver. Lin expects this number to rise dramatically in the coming years, and that is likely to lead to silver supply deficits for decades to come.

Lin points out that solar power is now the cheapest source of energy in many parts of the world and that all forecasts point to dramatic expansion of solar PV in the coming two decades. Conservative estimates forecast 300 gigawatts of solar PV production by 2027, up from the current level of about 200 gigawatts.

Management Team

Tyrone Docherty is President, Director and CEO of First Tellurium Corp. He previously served as President and CEO of Quinto Mining Inc. With limited resources in a difficult market environment, he raised more than $30 million and advanced its Quebec iron ore property to a viable project. Quinto later sold for $175 million. From 2012 to 2018, he was Director and Chairman of Mason Graphite Inc. He has worked in the financial and minerals markets for more than 30 years.

Tony Fogarassy, M.Sc. LL.M., is Chairman of First Tellurium Corp. He is a lawyer and a geologist. His extensive legal and technical expertise includes minerals, oil and gas, coal and renewable energy projects and environmental and aboriginal/indigenous law in North America, Africa and Asia. He graduated as gold medalist in geological sciences from the University of British Columbia and in law from the London School of Economics.

First Tellurium Corp. (OTCQB: FSTTF), closed Friday's trading session at $0.0902, off by 9.8%, on 23,550 volume. The average volume for the last 3 months is 23,550 and the stock's 52-week low/high is $0.071/$0.1765.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.